We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Warning Letters Trend Toward Component Testing, Contractor Oversight in 2022
Warning Letters Trend Toward Component Testing, Contractor Oversight in 2022
The top citations in FDA warning letters tend not to change radically from one year to the next, but the agency’s warning letters for fiscal 2022 hint at an increased focus on component testing and contractor oversight.